Log-In
|
Home
|
E-mail Alerts
|
My Headlines
|
Portfolio
Upgrade to StreetInsider Premium! - Free Trial
Home
Menu
JOIN
SI Premium
Ratings
Mergers
Earnings
Dividends
IPOs
Hedge Funds
Premium Letters
Send a Tip
License
JOIN
SI Premium
Full Feed View
Headline View
SI Premium Squawk Box
Alerts
Custom Headlines
Try SI PREMIUM
Upgrade Your Current Account
License
Calendars
Co. NDR/Event Calendar
Dividend Calendar
Earnings Calendar
Event Driven
FDA Calendar
Investor Conferences
IPO Calendar
Merger Arb
Ratings Calendar
Stock Split Calendar
Ratings
Analyst Comments
Hot Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Credit Ratings
Downgrade News
Hot Downgrades
New Coverage News
Hot New Coverage
Upgrade News
Hot Upgrades
More...
Mergers
Merger News
Hot M&A News
Private Equity
Rumors
SPAC News
Spinoffs
Merger Arbitrage
Event Driven
2021 Top M&A Deals
Top 50 Takeover Targets
More...
Earnings
Earnings Calendar
Earnings News
Hot Earnings
Guidance
Hot Guidance
Conference Calls
Earnings History Search
More...
Dividends
Dividend Calendar
Dividend News
Hot Dividends
Dividend Hike
Special Dividends
Stock Buybacks
Hot Stock Buybacks
Stock Splits
More...
IPOs
IPO News
Hot IPOs
Equity Offerings
Recent IPOs
Upcoming IPOs
2021 Top IPOs
More...
Hedge Funds
13D
13F
13G
Hedge Funds News
Hot Insider Trades
Insider Trades
More...
Premium Letters
Pulse Picks
Stealth Growth Insider
Send a Tip
License
QUICK LINKS :
Goldman Sachs Conviction Buy List
Warren Buffett News
Elliott Associates News
Follow @Street_Insider
More on ABBV
- Summary
- Chart
- Profile
- Historical
Data
- Earnings (
+18.2%
Growth)
- Ratings (6.9 Score)
- Holders
- Dividends (4.8% Yield)
- Event Driven Deals
- FDA
- FDA Archive
Upcoming Events
- Earnings
(4/30/21)
- Ex-Dividend
(4/14/2021)
- M&A
(11/30/-1 *Est)
- M&A
(12/31/16 *Est)
News
- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...
- 13Ds
- 13Fs
- 13Gs
- Accesswire
- Analyst Comments
- Analyst EPS Change
- Analyst EPS View
- Analyst PT Change
- Board Changes
- Brand News Today
- Business Wire
- CDN Newswire
- Commodities
- Conference Calls
- Contributors
- Corporate News
- Credit Ratings
- Dividend Cut
- Dividend Hike
- Dividends
- Downgrades
- Earnings
- Economic Data
- Equity Offerings
- ETFs
- FDA
- Fed
- FMR Wire
- FNMedia
- Forex
- General News
- Globe Newswire
- Hedge Funds
- Hot Buybacks
- Hot Comments
- Hot Corp. News
- Hot Dividends
- Hot Downgrades
- Hot Earnings
- Hot FDA News
- Hot Guidance
- Hot Hedge Fund News
- Hot Insider Trades
- Hot IPOs
- Hot List
- Hot M&A
- Hot Mgmt Changes
- Hot New Coverage
- Hot Upgrades
- Index Changes
- Insiders' Blog
- Intl Ratings
- Investor Brand Network
- IPOs
- KISS PR
- Life Enjoyed
- Litigation
- Management Comments
- MarijuanaStocks.com
- Market Check
- MarketIntelligence
- Momentum Movers
- MyWallSt
- MyWallSt
- New Coverage
- NewMediaWire
- NewMediaWire
- NewMediaWire
- Newsfile
- Option EPS Action
- Options
- OTC PR Wire
- PennyStocks.com
- Politics
- Press Advantage
- Press Releases
- Private Company News
- Private Equity
- PRNewswire
- Reuters
- SEC Filings
- Short Sales
- SI Newswire
- SPAC
- Special Dividends
- Special Reports
- Spinoffs
- Stock Market Press
- Stock Splits
- StockMarket.com
- Syndication Cloud
- Technicals
- Test PR Feeds
- The Financial Capital
- The Market Signal
- Trader Talk
- Trading Halts
- Upgrades
- Wired Release
AbbVie (NY:ABBV)
Delayed:
107.54
+1.44 (1.36%)
Prev. Close
$106.10
Today
6M
1Y
5Y
Open
$106.39
52 Wk High
$68.12
52 Wk Low
$50.71
Day High
$107.72
Day Low
$106.05
P/E
23.33
EPS
$4.61
Volume
5,977,406
Friends, Peers and Foes
(?)
:
AGN
,
IMAB
,
HARP
,
GILD
,
PFE
(more...)
ALERTS
|
RSS
All Recent
SI Reports
Press Releases
SEC Filings
Major News
Apr 7, 2021 09:01 AM
AbbVie (ABBV) Submits Regulatory Applications for SKYRIZI (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 09:01 AM
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 08:00 AM
AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
Apr 6, 2021 04:26 PM
RBC Capital Assumes Abbvie (ABBV) at Outperform
Apr 5, 2021 06:19 AM
AbbVie (ABBV) Announces Extension of Review for sNDA of Upadacitinib for Treatment of Moderate to Severe Atopic Dermatitis
Apr 2, 2021 05:18 PM
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Apr 1, 2021 04:44 PM
Form 4 AbbVie Inc. For: Mar 31 Filed by: Alpern Robert J
Apr 1, 2021 04:44 PM
Form 4 AbbVie Inc. For: Mar 31 Filed by: LIDDY EDWARD M
Apr 1, 2021 04:43 PM
Form 4 AbbVie Inc. For: Mar 31 Filed by: RAPP EDWARD J
Apr 1, 2021 08:45 AM
SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
View All Articles
Feb 3, 2021 07:39 AM
AbbVie (ABBV) Tops Q4 EPS by 6c, Offers FY Guidance
Oct 30, 2020 07:48 AM
AbbVie (ABBV) Tops Q3 EPS by 7c, Raises FY Guidance
Jul 31, 2020 07:45 AM
AbbVie (ABBV) Tops Q2 EPS by 15c, Issues Combined Company Guidance
May 1, 2020 07:45 AM
AbbVie (ABBV) Tops Q1 EPS by 17c, Confirms FY EPS Guidance
Feb 7, 2020 07:44 AM
AbbVie (ABBV) Tops Q4 EPS by 2c, FY20 EPS Guidance Beats
Nov 1, 2019 07:50 AM
AbbVie (ABBV) Tops Q3 EPS by 3c, Updates FY Guidance
Jul 26, 2019 07:44 AM
AbbVie (ABBV) Tops Q2 EPS by 6c, Revenue Beats, Updates FY Guidance
Jun 25, 2019 06:44 AM
AbbVie (ABBV) Announces Agreement to Acquire Allergan (AGN) in $63 Billion Deal
Jun 25, 2019 06:27 AM
AbbVie (ABBV) Nears Deal to Buy Allergan (AGN) for More Than $60 Billion - WSJ
Apr 25, 2019 07:43 AM
AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance
View All Major News
Apr 7, 2021 09:01 AM
AbbVie (ABBV) Submits Regulatory Applications for SKYRIZI (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 09:01 AM
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 08:00 AM
AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
Apr 6, 2021 04:26 PM
RBC Capital Assumes Abbvie (ABBV) at Outperform
Apr 5, 2021 06:19 AM
AbbVie (ABBV) Announces Extension of Review for sNDA of Upadacitinib for Treatment of Moderate to Severe Atopic Dermatitis
Apr 2, 2021 05:18 PM
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Apr 1, 2021 08:45 AM
SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
Apr 1, 2021 08:31 AM
AbbVie (ABBV) Announces NEJM Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ in Psoriatic Arthritis
Apr 1, 2021 08:31 AM
New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis
Mar 31, 2021 08:00 AM
AbbVie to Host First-Quarter 2021 Earnings Conference Call
View All Reports
Apr 7, 2021 09:01 AM
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Apr 7, 2021 08:00 AM
AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting
Apr 2, 2021 05:18 PM
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Apr 1, 2021 08:45 AM
SkinMedica® Launches Neck Correct Cream for Neck and Décolleté
Apr 1, 2021 08:31 AM
New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis
Mar 31, 2021 08:00 AM
AbbVie to Host First-Quarter 2021 Earnings Conference Call
Mar 30, 2021 08:00 AM
U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine
Mar 17, 2021 08:45 AM
AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with Active Psoriatic Arthritis
Feb 25, 2021 08:00 AM
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
Feb 24, 2021 07:15 PM
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
View All Press Releases
Apr 1, 2021 04:44 PM
Form 4 AbbVie Inc. For: Mar 31 Filed by: Alpern Robert J
Apr 1, 2021 04:44 PM
Form 4 AbbVie Inc. For: Mar 31 Filed by: LIDDY EDWARD M
Apr 1, 2021 04:43 PM
Form 4 AbbVie Inc. For: Mar 31 Filed by: RAPP EDWARD J
Mar 31, 2021 02:19 PM
Form PX14A6G AbbVie Inc. Filed by: Rhode Island Employees Retirement System Pool Trust
Mar 29, 2021 10:56 AM
Form PX14A6G AbbVie Inc. Filed by: Chevedden John
Mar 22, 2021 05:04 PM
Form DEFA14A AbbVie Inc.
Mar 22, 2021 05:01 PM
Form DEF 14A AbbVie Inc. For: May 07
Mar 12, 2021 05:03 PM
Form 8-K AbbVie Inc. For: Mar 12
Mar 9, 2021 05:27 PM
Form 4 AbbVie Inc. For: Mar 05 Filed by: Strom Carrie C
Mar 8, 2021 05:28 PM
Form PRE 14A AbbVie Inc. For: May 07
View All Filings
Entities mentioned with
ABBV
Twitter
|
View Related Stories »
Definitive Agreement
|
View Related Stories »
FDA
|
View Related Stories »
Earnings
|
View Related Stories »
Dividend
|
View Related Stories »
Morgan Stanley
|
View Related Stories »
Goldman Sachs
|
View Related Stories »
JPMorgan
|
View Related Stories »
Options
|
View Related Stories »
Jefferies & Co
|
View Related Stories »
Deutsche Bank
|
View Related Stories »
Standard & Poor's
|
View Related Stories »
BMO Capital
|
View Related Stories »
Citi
|
View Related Stories »
Credit Suisse
|
View Related Stories »
Barclays
|
View Related Stories »
Cowen & Co
|
View Related Stories »
Piper Jaffray
|
View Related Stories »
UBS
|
View Related Stories »
Wells Fargo
|
View Related Stories »
Pre Market Movers
|
View Related Stories »
RBC Capital
|
View Related Stories »
Stock Buyback
|
View Related Stories »
S3
|
View Related Stories »
13G
|
View Related Stories »
Show More...
View All Entities